Assessing histone demethylase inhibitors in cells: lessons learned
Background<br/> Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders. The first KDM inhibitors for KDM1 have entered clinical trials, and effor...
Main Authors: | Hatch, S, Yapp, C, Montenegro, R, Savitsky, P, Gamble, V, Tumber, A, Ruda, G, Bavetsias, V, Fedorov, O, Atrash, B, Raynaud, F, Lanigan, R, Carmichael, L, Tomlin, K, Burke, R, Westway, S, Brown, J, Prinjha, R, Martinez, E, Oppermann, U, Schofield, C, Bountra, C, Kawamura, A, Blagg, J, Brennan, P, Rossanese, O, Müller, S |
---|---|
Format: | Journal article |
Published: |
BioMed Central
2017
|
Similar Items
-
8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors
by: Bavetsias, V, et al.
Published: (2016) -
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays
by: Le Bihan, Y-V, et al.
Published: (2019) -
Development of homogeneous luminescence assays for histone demethylase catalysis and binding.
by: Kawamura, A, et al.
Published: (2010) -
Development of homogeneous luminescence assays for histone demethylase catalysis and binding.
by: Kawamura, A, et al.
Published: (2010) -
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
by: Kawamura, A, et al.
Published: (2017)